Log In
Print
BCIQ
Print
Print this Print this
 

Neoxy, oxybutynin hydrochloride (HOB-294)

  Manage Alerts
Collapse Summary General Information
Company Hisamitsu Pharmaceutical Co. Inc.
DescriptionTransdermal formulation of oxybutynin, a competitive antagonist of M1, M2 and M3 subtypes of the muscarinic acetylcholine receptor
Molecular Target Muscarinic acetylcholine receptor M1 (CHRM1) (HM1) ; Muscarinic acetylcholine receptor M2 (CHRM2) (HM2)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation

Partner

Asahi Kasei Pharma Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today